Advances in genomics research and increasing adoption of high-throughput sequencing technologies are driving the demand for next-generation sequencing platforms across China’s life sciences and biotechnology sectors. Against this backdrop, the next generation sequencers market in China is projected to grow at a 9% compound annual growth rate (CAGR) between 2026 and 2036, according to GlobalDataU, a leading intelligence and productivity platform.

GlobalData’s report, “Next Generation Sequencers Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2036,” reveals that China accounted for nearly 32% of the Asia-Pacific (APAC) next-generation sequencers market in 2025, supported by expanding genomics research activities and increasing adoption of advanced sequencing technologies across academic and clinical research settings.

Chinese biotechnology company MGI Tech has recently acquired STOmics and CycloneSEQ to expand its technological capabilities in spatial biology and nanopore sequencing. The move broadens the scope of its genomics portfolio and strengthens capabilities across multiple sequencing approaches.

Divya Soni, Medical Devices Analyst at GlobalData, comments: “As life sciences research increasingly adopts multi-omics approaches, there is growing push towards more integrated workflows linking sequencing and spatial biology, particularly in leading research institutions in China. Spatial technologies are seeing faster adoption, while long-read sequencing is expanding more selectively due to higher cost and operational complexity.

“The combined use of these approaches remains at an early stage and is largely limited to advanced research settings. China continues to be an important hub for genomics innovation, with domestic companies expanding into complementary platforms; however, adoption is influenced by procurement structures, cost consideration, and broader market access dynamics.”

STOmics contributes spatial multi-omics capabilities through its Stereo-seq platform, enabling high-resolution spatial analysis of gene expression across large tissue sections for applications including developmental biology, neuroscience, and disease research. Meanwhile, CycloneSEQ develops nanopore sequencing platforms for long-read sequencing, including the G100-ER system for smaller-scale use and the higher-throughput G400-ER system. The G100-ER platform has received CE marking under the European Union’s In Vitro Diagnostic Regulation (IVDR), supporting its readiness for regulated markets.

Soni concludes: “The addition of spatial omics and nanopore sequencing alongside established sequencing platforms highlights the industry’s growing focus on more comprehensive genomic research capabilities. As companies expand their technological portfolios, such developments can strengthen research infrastructure and support gradual adoption of advanced sequencing tools across life sciences and biotechnology applications.”